Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel, Open-label, Positive Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in HER2-negative Locally Advanced or Metastatic Breast Cancer Patients With Germline BRCA Mutations

NCT05420779 is registered in ClinicalTrials.gov with Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05420779
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05420779 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel, Open-label, Positive Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of TSL-1502 Capsules in HER2-negative Locally Advanced or Metastatic Breast Cancer Patients With Germline BRCA Mutations
Lead sponsor
Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2022
Completion date
June 30, 2026
Enrollment
125 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer metastatic